Business Wire - CyDex Announces Captisol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia® Recently Approved for Marketing in Europe
Tuesday, November 18th, 2008 LENEXA, Kan. — CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced that a subcutaneous injection formulation of the veterinary anti-emetic medication Cerenia([R])(maropitant) from Pfizer Limited contains CyDex’s Captisol([R])-enabling technology.
On September 29, 2006, the European Medicines Agency approved both the subcutaneous injection and tablet formulations of Pfizer’s Cerenia for marketing through…
